# EDGAR Filing Document

**Accession Number:** 0001757499
**File Stem:** 0001493152-26-028301
**Filing Date:** 2026-6
**Character Count:** 11026
**Document Hash:** dd689fe35e38f0346b87a97c136374a2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-028301.hdr.sgml**: 20260611

**ACCESSION NUMBER**: 0001493152-26-028301

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260610

**ITEM INFORMATION**: Material Modifications to Rights of Security Holders

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260611

**DATE AS OF CHANGE**: 20260611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Shuttle Pharmaceuticals Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001757499
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41488
- **FILM NUMBER:** 261083960

**BUSINESS ADDRESS:**
- **STREET 1:** 401 PROFESSIONAL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20879
- **BUSINESS PHONE:** (240) 403-4212

**MAIL ADDRESS:**
- **STREET 1:** 401 PROFESSIONAL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20879

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of report (date of earliest event reported): June 10, 2026

**SHUTTLE PHARMACEUTICALS HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

<u>Delaware</u> <u>001-41488</u> <u>82-5089826</u> <br> (State or other jurisdiction of incorporation) Commission File Number (IRS Employer Identification No.)

401 Professional Drive, Suite 260

Gaithersburg, MD 20879

(Address of principal executive offices) (Zip Code)

(240) 430-4212

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock $0.00001 per share | SHPH | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 3.03 Material Modification to Rights of Security Holders.**

To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.

**Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

At the 2026 annual meeting of stockholders of Shuttle Pharmaceuticals Holdings, Inc. (the "Company") held on May 21, 2026 (the "Annual Meeting"), the Company's stockholders approved a proposal authorizing the board of directors of the Company (the "Board"), in its sole discretion, to effect one or more reverse stock splits of the outstanding shares of the Company's common stock, par value, $0.00001 per share (the "Common Stock"), at a cumulative reverse split ratio in the range of one-for-two (1:2) to one-for-one hundred and fifty (1:150), as determined by the Board, whereby every two to one hundred and fifty shares of the issued and outstanding Common Stock will be combined into one share of issued and outstanding Common Stock. The voting results of the Annual Meeting were reported on a Form 8-K filed with the Securities and Exchange Commission on May 27, 2026.

Pursuant to such authority granted by the Company's stockholders at the Annual Meeting, on June 1, 2026, the Board approved a one-for-ten (1:10) reverse stock split (the "Reverse Stock Split") of the Common Stock and on June 10, 2026, the Company filed a certificate of amendment to amend the certificate of incorporation of the Company (the "Certificate of Amendment") with the Secretary of State of the State of Delaware, with an effective date of June 11, 2026 (the "Effective Date"). The Reverse Stock Split became effective at the start of trading on June 11, 2026 (the "Effective Time"). Following the Reverse Stock Split, every ten (10) shares of the Company's issued and outstanding Common Stock immediately prior to the Effective Time were automatically reclassified into one (1) share of Common Stock, without any change in the par value per share. The Reverse Stock Split reduced the number of shares of Common Stock issuable upon the exercise or vesting of the Company's outstanding warrants, restricted stock units and convertible preferred stock in proportion to the ratio of the Reverse Stock Split and caused a proportionate increase in the exercise or conversion prices of such convertible securities, as applicable. The Reverse Stock Split did not change the total number of authorized shares of Common Stock or preferred stock.

No fractional shares were issued as a result of the Reverse Stock Split. Stockholders who otherwise would be entitled to receive a fractional share in connection with the Reverse Stock Split received one full share of the post-Reverse Stock Split Common Stock in lieu of such fractional share.

VStock Transfer LLC is acting as exchange agent for the Reverse Stock Split and will notify stockholders of record regarding the Reverse Stock Split. Stockholders who hold their shares in book-entry form or in "street name" (through a broker, bank or other holder of record) are not required to take any action.

Commencing on June 11, 2026, trading of the Company's Common Stock continued on The Nasdaq Capital Market on a Reverse Stock Split-adjusted basis. The new CUSIP number for the Company's Common Stock following the Reverse Stock Split is 825693500.

The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, which is filed as Exhibit 3.1 to this report and incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(d) Exhibits*

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 3.1 | [Certificate of Amendment of Shuttle Pharmaceuticals Holdings, Inc](ex3-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| Dated: | June 11, 2026 |
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | SHUTTLE PHARMACEUTICALS HOLDINGS, INC. |
| By: | */s/ Christopher Cooper* |
| Name: | Christopher Cooper |
| Title: | Interim Co-Chief Executive Officer |

---

## Exhibit 3.1

**Exhibit 3.1**

**CERTIFICATE OF AMENDMENT TO<br> AMENDED AND RESTATED**

**CERTIFICATE OF INCORPORATION**

**OF**

**SHUTTLE PHARMACEUTICALS HOLDINGS, INC.**

The undersigned, being the Interim Co-Chief Executive Officer of Shuttle Pharmaceuticals Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the "Corporation") does hereby amend and certify as follows:

&nbsp;&nbsp;&nbsp;&nbsp;1. That
 the name of the Corporation is Shuttle Pharmaceuticals Holdings, Inc. and that the Corporation
 was originally incorporated pursuant to the Delaware General Corporation Law ("DGCL")
 on April 5, 2018.

2. That
 this Certificate of Amendment, which is being filed to amend the Corporation's amended
 and restated certificate of incorporation, dated June 8, 2018 (the "Amended and Restated
 Certificate of Amendment"), as amended on March 31, 2022, June 22, 2022, August 6,
 2024 and June 12, 2025, has been duly adopted by the Corporation's board of directors
 and stockholders in accordance with the provisions of Section 242 of the DGCL.

Article FOURTH of the Amended and Restated Certificate of Incorporation will be amended to replace Section 4.5 as follows:

"4.5 <u>Reverse Stock Split</u>. Upon the effectiveness (the "*Effective Time*") of this Certificate of Amendment pursuant to Section 242 of the General Corporation Law of the State of Delaware, each ten (10) shares of the Corporation's common stock, par value of $0.00001 per share, issued and outstanding immediately prior to the Effective Time (the "*Old Common Stock*") shall automatically and without further action on the part of the Corporation or any holder of Old Common Stock, be reclassified, combined and changed into one (1) fully-paid and nonassessable share of common stock, par value of $0.00001 per share (the "*New Common Stock*"), subject to the treatment of fractional share interests as described below (the "reverse stock split"). From and after the Effective Time, certificates representing the Old Common Stock shall represent the number of shares of New Common Stock into which such Old Common Stock shall have been combined pursuant to this Certificate of Amendment. Holders who otherwise would be entitled to receive fractional share interest of New Common Stock upon the effectiveness of the reverse stock split shall be entitled to receive a shole share of New Common Stock in lieu of any fractional shares created as a result of such reverse stock split."

&nbsp;&nbsp;&nbsp;&nbsp;3. That
 this Certificate of Amendment shall be effective as of 12:01 a.m. ET on June 11, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;4. Except
 as set forth in this Certificate of Amendment, the Amended and Restated Certificate of Incorporation,
 as previously amended, remains in full force and effect.

**IN WITNESS WHEREOF**, this Certificate of Amendment has been executed by a duly authorized officer of the Corporation on this 10th day of June 2026.

---

| |
|:---|
| */s/ Christopher Cooper* |
| **Christopher Cooper** |
| *Interim Co-Chief Executive Officer* |

---